348 related articles for article (PubMed ID: 30984204)
1. NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment.
Frazao A; Rethacker L; Messaoudene M; Avril MF; Toubert A; Dulphy N; Caignard A
Front Immunol; 2019; 10():661. PubMed ID: 30984204
[TBL] [Abstract][Full Text] [Related]
2. NKG2D signaling in cancer immunosurveillance.
López-Soto A; Huergo-Zapico L; Acebes-Huerta A; Villa-Alvarez M; Gonzalez S
Int J Cancer; 2015 Apr; 136(8):1741-50. PubMed ID: 24615398
[TBL] [Abstract][Full Text] [Related]
3. NKG2D CARs as cell therapy for cancer.
Sentman CL; Meehan KR
Cancer J; 2014; 20(2):156-9. PubMed ID: 24667963
[TBL] [Abstract][Full Text] [Related]
4. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
5. NKG2D and Its Ligands: "One for All, All for One".
Zingoni A; Molfetta R; Fionda C; Soriani A; Paolini R; Cippitelli M; Cerboni C; Santoni A
Front Immunol; 2018; 9():476. PubMed ID: 29662484
[TBL] [Abstract][Full Text] [Related]
6. NKG2D ligands as therapeutic targets.
Spear P; Wu MR; Sentman ML; Sentman CL
Cancer Immun; 2013; 13():8. PubMed ID: 23833565
[TBL] [Abstract][Full Text] [Related]
7. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
8. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
Ding H; Yang X; Wei Y
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
[TBL] [Abstract][Full Text] [Related]
9. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
Lazarova M; Wels WS; Steinle A
Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
[TBL] [Abstract][Full Text] [Related]
10. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection.
Deng W; Gowen BG; Zhang L; Wang L; Lau S; Iannello A; Xu J; Rovis TL; Xiong N; Raulet DH
Science; 2015 Apr; 348(6230):136-9. PubMed ID: 25745066
[TBL] [Abstract][Full Text] [Related]
11. Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells.
Guo C; Wang X; Zhang H; Zhi L; Lv T; Li M; Lu C; Zhu W
Mol Immunol; 2019 Oct; 114():108-113. PubMed ID: 31351411
[TBL] [Abstract][Full Text] [Related]
12. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.
Chitadze G; Bhat J; Lettau M; Janssen O; Kabelitz D
Scand J Immunol; 2013 Aug; 78(2):120-9. PubMed ID: 23679194
[TBL] [Abstract][Full Text] [Related]
13. Advances in NKG2D ligand recognition and responses by NK cells.
Le Bert N; Gasser S
Immunol Cell Biol; 2014 Mar; 92(3):230-6. PubMed ID: 24445601
[TBL] [Abstract][Full Text] [Related]
14. Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis.
Molfetta R; Quatrini L; Santoni A; Paolini R
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28767057
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy using NKG2D and DNAM-1 systems.
Morisaki T; Onishi H; Katano M
Anticancer Res; 2012 Jun; 32(6):2241-7. PubMed ID: 22641658
[TBL] [Abstract][Full Text] [Related]
16. NKG2D and its ligands.
Obeidy P; Sharland AF
Int J Biochem Cell Biol; 2009 Dec; 41(12):2364-7. PubMed ID: 19631280
[TBL] [Abstract][Full Text] [Related]
17. Viral inhibitors of NKG2D ligands for tumor surveillance.
Chávez-Blanco A; Chacón-Salinas R; Dominguez-Gomez G; Gonzalez-Fierro A; Perez-Cardenas E; Taja-Chayeb L; Trejo-Becerril C; Duenas-Gonzalez A
Expert Opin Ther Targets; 2016 Nov; 20(11):1375-1387. PubMed ID: 27322108
[TBL] [Abstract][Full Text] [Related]
18. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
19. NKG2D and its ligands in cancer.
Dhar P; Wu JD
Curr Opin Immunol; 2018 Apr; 51():55-61. PubMed ID: 29525346
[TBL] [Abstract][Full Text] [Related]
20. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
Front Immunol; 2019; 10():2361. PubMed ID: 31649672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
